Identification of anti-TNFα peptides with consensus sequence

Biochemical and Biophysical Research Communications

Volumn 310, Issue 4, 2003, Pages 1181-1187

  Zhang, Jie ^a   Zheng, Li ^a   Zhao, An ^a   Gao, Bo ^a   Liu, Nong Le ^a   Wang, Fang ^a   Dong, Jie ^a   Xin, Zhong Tao ^a   Shao, Ning Sheng ^a   Wang, Hui Xin ^a   Xue, Yan Ning ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Antagonist; Binding peptides; Phage display; TNF ; TNF receptor

Indexed keywords

ANTIINFLAMMATORY AGENT; ASPARAGINYLTYROSYLARGINYLLEUCYLHISTIDYLGLUTAMYLLEUCYLTYROSYLGLUTAMINYLSERYL TRYPTOPHYLHISTIDINE; ASPARAGINYLTYROSYLLYSYLHISTIDYLALANYLGLUTAMYLLEUCYLTYROSYLGLUTAMINYLSERYLTR YPTOPHYLHISTIDINE; GLUTAMINYLPROLYLLEUCYLHISTIDYLGLUTAMYLISOLEUCYLPHENYLALANYLPHENYLALANYLHIST IDYLPHENYLALANYLMETHIONYLTYROSINE; GLUTATHIONE TRANSFERASE; GLYCYLLEUCYLASPARAGINYLMETHIONYLHISTIDYLGLUTAMYLLEUCYLTYROSYLMETHIONYLHISTI DYLTRYTOPHYLALANINE; TUMOR NECROSIS FACTOR RECEPTOR 1; TYROSYLALANYLARGINYLPROLYLHISTIDYLGLUTAMYLLEUCYLPHENYLALANYLLEUCYLLEUCYLLEU CYLARGININE; UNCLASSIFIED DRUG; VALYLPROLYLPROLYLLEUCYLHISTIDYLGLUTAMYLLEUCYLTYROSYLLEUCYLMETHIONYLHISTIDYL TRYPTOPHAN; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE; PRIMER DNA; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG RECEPTOR BINDING; ELUTION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; PROTEIN STRUCTURE; BACTERIOPHAGE; CHEMISTRY; DRUG ANTAGONISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

BACTERIOPHAGES; BASE SEQUENCE; CONSENSUS SEQUENCE; DNA PRIMERS; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDES; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141892639     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.09.141     Document Type: Article

References (32)

1. Balkwill F.R., Burke F. The cytokine network. Immunol. Today. 109:1989;299-304.
2. Beutler B.A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 26:1999;16-21.
3. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 87:1990;3127-3131.
4. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334:1996;1717-1725.
5. Baert F.J., Rutgeerts P.R. Anti-TNF strategies in Crohn's disease: mechanism, clinical effects, indications. Int. J. Colerectal Dis. 14:1999;47-51.
6. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 50:2000;229-235.
7. Seymour H.E., Worsley A., Smith J.M., Thomas S.H. Anti-TNF agents for rheumatoid arthritis. Br. J. Clin. Pharmacol. 51:2001;201-208.
8. Taylor P.C. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol. Biotechnol. 19:2001;153-168.
9. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2:2002;364-371.
10. Braun J., Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther. 3:2003;141-168.
11. Van Deventer S.J. Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of inflixmimab. Aliment. Pharmacol. Ther. 13(Suppl.):1999;3-8.
12. Mease P.J. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Ther. Lett. 8:2003;1-4.
13. Wolf R., Matz H., Orion E., Ruocco V. Anti-TNF therapies-the hope of tomorrow. Clin. Dermatol. 20:2002;522-530.
14. Shanahan F. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for). Inflamm. Bowel Dis. 6:2000;137-139.
15. Antoni C., Braun J. Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol. 20:2002;S152-S157.
16. Devos S.A., Van Den Bossche N., De Vos M., Naeyaert J.M. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology. 206:2003;388-390.
17. Debandt M., Vittecoq O., Descamps V., Le Loet X., Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin. Rheumatol. 22:2003;56-61.
18. Hwang C.D., Gatanaga M., Innins E.K., Yamamoto R.S., Granger G.A., Gatanaga T. A 20 amino acid synthetic peptide of a region from the 55. kDa human TNF receptor inhibits cytolytic and binding activities of recombinant human tumour necrosis factor in vitro Proc. R. Soc. Lond. B. Biol. Sci. 245:1991;115-119.
19. Lie B.L., Tunemoto D., Hemmi H., Mizukami Y., Fukuda H., Kikuchi H., Kato S., Numao N. Identification of the binding site of 55kDa tumor necrosis factor receptor by synthetic peptides. Biochem. Biophys. Res. Commun. 188:1992;503-509.
20. Takasaki W., Kajino Y., Kajino K., Murali R., Greene M.I. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat. Biotechnol. 15:1997;1266-1270.
21. Manoutcharian K., Gevorkian G., Cano A., Almagro J.C. Phage displayed biomolecules as preventive and therapeutic agents. Curr. Pharm. Biotechnol. 2:2001;217-223.
22. Adda C.G., Anders R.F., Tilley L., Foley M. Random sequence libraries displayed on phage: identification of biologically important molecules. Comb. Chem. High Throughput Screen. 5:2002;1-14.
23. Chirinos-Rojas C.L., Steward M.W., Partidos C.D. Use of a solid-phase random peptide library to identify inhibitors of TNF-alpha mediated cytotoxicity in vitro. Cytokine. 9:1997;226-232.
24. Chirinos-Rojas C.L., Steward M.W., Partidos C.D. A peptidomimetic antagonist of TNFα-mediated cytotoxicity identified from a phage-displayed random peptide library. J. Immuol. 161:1998;5621-5626.
25. Chirinos-Rojas C.L., Steward M.W., Partidos C.D. A phage-displayed mimotope inhibits tumor necrosis factor-induced cytotoxicity more effectively than the free mimotope. Immunology. 96:1999;109-113.
26. Reed C., Fu Z.Q., Wu J., Xue Y.N., Harrison R.W., Chen M.J., Weber I.T. Crystal structure of TNF-alpha mutant R31D with greater affinity for receptor R1 compared with R2. Protein Eng. 10:1997;1101-1107.
27. Sidhu S.S. Engineering M13 for phage display. Biomol. Eng. 18:2001;57-63.
28. Guan K.L., Dixon J.E. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal. Biochem. 192:1991;262-267.
29. Arandjelovic S., Freed T.A., Gonias S.L. Growth factor-binding sequence in human alpha(2)-macroglobulin targets the receptor-binding site in transforming growth factor-beta. Biochemistry. 42:2003;6121-6127.
30. Chae Y.K., Cho K.S., Chun W. A prionogenic peptide derived from Sup35 can force the whole GST fusion protein to show amyloid characteristics. Protein Pept. Lett. 9:2002;315-321.
31. Cochran A.G. Antagonists of protein-protein interactions. Chem. Biol. 7:2000;R85-R94.
32. Wrighton N.C., Farrell F.X., Chang R., Kashyap A.K., Barbone F.P., Mulcahy L.S., Johnson D.L., Barrett R.W., Jolliffe L.K., Dower W.J. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 273:1996;458-464.